V Hess
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
Ruhstaller T, Mingrone W, Montemurro M, Girschikofsky M, Schmidt S, Bitzer M, Bedenne L, Brauchli P, Stahl M, Hess V, Mariette C, Hawle H, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild J, Schnider A, Plasswilm L, Budach W, Eisterer W, Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol 2018; 29:1386-1393.
01.06.2018Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
01.06.2018Ann Oncol 2018; 29:1386-1393
Ruhstaller Thomas, Mingrone W, Montemurro M, Girschikofsky M, Schmidt S C, Bitzer M, Bedenne L, Brauchli P, Stahl M, Hess V, Mariette C, Hawle H, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild J R, Schnider A, Plasswilm L, Budach W, Eisterer W, Swiss Group for Clinical Cancer Research (SAKK), the German Esophageal Cancer Study Group, the Austrian ‘Arbeitsgemeinschaft Medikamentöse Tumortherapie’ (AGMT), and the Fédération Francophone de Cancérologie Digestive (FFCD)/Fédération de Recherche en Ch
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
Koeberle D, Kollar A, Saletti P, Roth A, Früh M, Kueng M, Popescu R, Schacher S, Hess V, Moosmann P, Anchisi S, Betticher D, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Herrmann R. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol 2015; 26:709-14.
20.01.2015Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
20.01.2015Ann Oncol 2015; 26:709-14
Koeberle D, Kollar A, Saletti P, Roth A, Früh Martin, Kueng M, Popescu R A, Schacher S, Hess V, Moosmann P, Anchisi S, Betticher D C, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Herrmann R
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
Ruhstaller T, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle D, Balmermajno S, Pestalozzi B, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J, Widmer L, Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8.
01.09.2009Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
01.09.2009Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8
Ruhstaller Thomas, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle Dieter, Balmermajno S, Pestalozzi B C, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J C, Widmer L, Swiss Group for Clinical Cancer Research (SAKK)
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
Borner M, Mingrone W, Lanz D, Dietrich D, Kappeler A, Roth A, Ruhstaller T, Caspar C, Pestalozzi B, Helbling D, Trojan A, Hess V, Rauch D, Saletti P, von Moos R, Koeberle D, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:1288-92.
01.07.2008Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
01.07.2008Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:1288-92
Borner M, Mingrone W, Lanz D, Dietrich D, Kappeler A, Roth A, Ruhstaller Thomas, Caspar C, Pestalozzi B, Helbling D, Trojan A, Hess V, Rauch D, Saletti P, von Moos R, Koeberle D, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer
Köberle D, Rust C, Bieri G, Neuweiler J, Terraciano L, Ruhstaller T, Heitzmann F, Hess V, Winterhalder R, von Moos R, Burkhard R, Toepfer M. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. British journal of cancer 2008; 98:1204-9.
08.04.2008Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer
08.04.2008British journal of cancer 2008; 98:1204-9
Köberle Dieter, Rust C, Bieri G, Neuweiler Jörg, Terraciano L, Ruhstaller Thomas, Heitzmann F, Hess V, Winterhalder R, von Moos R, Burkhard R, Toepfer M
Das Ösophaguskarzinom
Hess V. Das Ösophaguskarzinom. Schweizer Zeitschrift für Onkologie 2006; 3:6-12.
01.01.2006Das Ösophaguskarzinom
01.01.2006Schweizer Zeitschrift für Onkologie 2006; 3:6-12
Hess V
Das Ösophaguskarzinom
Ruhstaller T, Hess V. Das Ösophaguskarzinom. Schweizer Zeitschrift für Onkologie 2006; 3:6-12.
01.01.2006Das Ösophaguskarzinom
01.01.2006Schweizer Zeitschrift für Onkologie 2006; 3:6-12
Ruhstaller Thomas, Hess V